National Bank acquires over four hundred thousand own shares in recent buyback

Gikas Hardouvelis Chair of the Board Non-Executive National Bank of Greece SA
Gikas Hardouvelis Chair of the Board Non-Executive - National Bank of Greece SA
0Comments

National Bank of Greece S.A. has announced the purchase of 481,575 common shares as part of its share buyback program. This initiative follows resolutions from the Annual General Meeting held on May 30, 2025, and the subsequent approval by the Single Supervisory Mechanism (SSM) of the European Central Bank on May 28, 2025.

The shares were acquired between June 25 and July 2, 2025, at an average price of €11.0300 per share, totaling a cost of €5,311,780.81. The bank intends to cancel these shares in accordance with Law 4548/2018.

The transactions over this period are detailed as follows:

– On June 25: 75,000 shares at €11.1981 each for a total of €839,857.50.
– On June 26: Another batch of 75,000 shares at €11.1103 each for a total cost of €833,272.50.
– On June 27: Again purchasing 75,000 shares at €10.9725 each costing €822,937.50.
– On June 30: Acquired were 76,623 shares priced at €10.9214 each totaling €836,830.43.
– On July 1: Bought were another set of 75,000 shares at a rate of €10.9156 amounting to €818,670.
– Finally on July 2: Purchased were a further set comprising of104,952 shares priced at€11 .0547 for an overall sum reaching€1 ,160 ,212 .87 .

Following these transactions within this timeframe alone now positions National Bank directly holding onto some4703244own owned representing around half percent (.51%)of entire company’s existing capital structure thus far

This announcement aligns with EU Regulation No596 /2014 alongside Commission Delegated Regulation (EU)2016 /1052 also adhering Resolution Number Twenty-Five(25) Stock Markets Steering Committee Athens Exchange directives



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.